Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery

BACKGROUND: In early-onset or familial breast cancer, NGS is routinely used for germline mutation screening. However, detection of pathogenic variants at low allele frequencies may complicate clinical diagnosis. CASE PRESENTATION: We report a case of advanced breast cancer in which a TP53 mutation identified in whole blood likely reflects tumor-derived circulating tumor DNA (ctDNA) rather than a true germline event. A 45-year-old Chinese female with invasive lobular carcinoma underwent germline mutation analysis using NGS on peripheral blood, targeting 23 cancer-related genes including TP53. NGS identified a TP53 missense mutation (NM_000546.6:c.818G>A; p.R273H) at a variant allele frequency of 26.28%. Validation was attempted via sanger sequencing, and NGS was subsequently repeated on isolated peripheral blood leukocytes after plasma removal to ascertain the mutation's origin. Although the initial NGS assay detected the TP53 p.R273H mutation at 26.28%, sanger sequencing did not confirm its presence. Moreover, NGS performed on plasma-depleted leukocytes yielded a negative result. This unexpected divergence strongly suggests that the detected variant originated from tumor-derived cfDNA rather than representing a bona fide germline mutation. CONCLUSIONS: This case demonstrates that high levels of tumor-derived cfDNA in advanced breast cancer can confound germline mutation detection, leading to discordant sequencing results. Our findings highlight the importance of employing complementary validation strategies and cautious interpretation of molecular data to avoid diagnostic errors and unnecessary interventions. Our case highlights critical pre-analytical and analytical considerations in molecular diagnostics, urging laboratory professionals to adopt rigorous validation protocols in patients with high tumor burden.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Laboratory Analysis
Published
2026-11-17
DOI
https://doi.org/10.1002/jcla.70374
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery

Jiajia Song, Yanjun Si, Tangyuheng Liu, Hao Chen
Journal of Clinical Laboratory Analysis
BRCA gene mutations in cancer
article

Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery

Jiajia Song, Yanjun Si, Tangyuheng Liu, Hao Chen
article en

Abstract

BACKGROUND: In early-onset or familial breast cancer, NGS is routinely used for germline mutation screening. However, detection of pathogenic variants at low allele frequencies may complicate clinical diagnosis. CASE PRESENTATION: We report a case of advanced breast cancer in which a TP53 mutation identified in whole blood likely reflects tumor-derived circulating tumor DNA (ctDNA) rather than a true germline event. A 45-year-old Chinese female with invasive lobular carcinoma underwent germline mutation analysis using NGS on peripheral blood, targeting 23 cancer-related genes including TP53. NGS identified a TP53 missense mutation (NM_000546.6:c.818G>A; p.R273H) at a variant allele frequency of 26.28%. Validation was attempted via sanger sequencing, and NGS was subsequently repeated on isolated peripheral blood leukocytes after plasma removal to ascertain the mutation's origin. Although the initial NGS assay detected the TP53 p.R273H mutation at 26.28%, sanger sequencing did not confirm its presence. Moreover, NGS performed on plasma-depleted leukocytes yielded a negative result. This unexpected divergence strongly suggests that the detected variant originated from tumor-derived cfDNA rather than representing a bona fide germline mutation. CONCLUSIONS: This case demonstrates that high levels of tumor-derived cfDNA in advanced breast cancer can confound germline mutation detection, leading to discordant sequencing results. Our findings highlight the importance of employing complementary validation strategies and cautious interpretation of molecular data to avoid diagnostic errors and unnecessary interventions. Our case highlights critical pre-analytical and analytical considerations in molecular diagnostics, urging laboratory professionals to adopt rigorous validation protocols in patients with high tumor burden.

Journal of Clinical Laboratory Analysis
Sichuan University (CN), West China Hospital of Sichuan University (CN)
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon